Cargando…

CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation

SIMPLE SUMMARY: In pancreatic cancer, CUX1 acts as an important mediator of tumor cell proliferation and resistance to apoptosis. Using two different mouse models for the prevalent CUX1 isoforms p200 and p110, we identified p110 CUX1 as the major isoform promoting pancreatic cancer formation in the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griesmann, Heidi, Mühl, Sebastian, Riedel, Jan, Theuerkorn, Katharina, Sipos, Bence, Esposito, Irene, Vanden Heuvel, Gregory B., Michl, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158495/ https://www.ncbi.nlm.nih.gov/pubmed/34070180 http://dx.doi.org/10.3390/cancers13102462

Ejemplares similares

The role of CUX1 in antagonizing NF-κB signaling in TAMs
por: Kühnemuth, Benjamin, et al.
Publicado: (2014)

IGF2BP1 Promotes Proliferation of Neuroendocrine Neoplasms by Post-Transcriptional Enhancement of EZH2
por: Sperling, Florian, et al.
Publicado: (2022)

PARP1-Erk synergism in proliferating cells
por: Visochek, Leonid, et al.
Publicado: (2018)

CUX1—Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors
por: Krug, Sebastian, et al.
Publicado: (2020)

Cux1 regulation of the cyclin kinase inhibitor p27(kip1) in polycystic kidney disease is attenuated by HDAC inhibitors
por: Livingston, Safia, et al.
Publicado: (2019)

Gender-specific changes of the gut microbiome correlate with tumor development in murine models of pancreatic cancer
por: Kaune, Tom, et al.
Publicado: (2023)

Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway
por: Conti, Annalisa, et al.
Publicado: (2015)

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
por: Ozkan-Dagliyan, Irem, et al.
Publicado: (2020)

Inactivating CUX1 mutations promote tumorigenesis
por: Wong, Chi C., et al.
Publicado: (2013)

Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis
por: Egidi, Maren Juliane, et al.
Publicado: (2023)

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation
por: Lionetti, Marta, et al.
Publicado: (2015)

STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway
por: Wang, Zhenlin, et al.
Publicado: (2019)

Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway
por: Hu, Haoyue, et al.
Publicado: (2020)

RASSF9 promotes NSCLC cell proliferation by activating the MEK/ERK axis
por: Yuan, Jun, et al.
Publicado: (2021)

CUX2 functions as an oncogene in papillary thyroid cancer
por: Sun, Yihan, et al.
Publicado: (2018)

The DNA repair function of CUX1 contributes to radioresistance
por: Ramdzan, Zubaidah M., et al.
Publicado: (2017)

CUX1, A Controversial Player in Tumor Development
por: Liu, Ning, et al.
Publicado: (2020)

miR-143 Targeting CUX1 to Regulate Proliferation of Dermal Papilla Cells in Hu Sheep
por: Hu, Tingyan, et al.
Publicado: (2021)

KIF15 promotes bladder cancer proliferation via the MEK–ERK signaling pathway
por: Zhao, Hongda, et al.
Publicado: (2019)

KIF15 promotes pancreatic cancer proliferation via the MEK–ERK signalling pathway
por: Wang, Jie, et al.
Publicado: (2017)

BCKDK Promotes Ovarian Cancer Proliferation and Migration by Activating the MEK/ERK Signaling Pathway
por: Li, Huashun, et al.
Publicado: (2022)

Deregulation of a Network of mRNA and miRNA Genes Reveals That CK2 and MEK Inhibitors May Synergize to Induce Apoptosis KRAS-Active NSCLC
por: Gober, Madeline Krentz, et al.
Publicado: (2019)

Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
por: Weißbach, Susann, et al.
Publicado: (2020)

Effect of CUX1 on the Proliferation of Hu Sheep Dermal Papilla Cells and on the Wnt/β-Catenin Signaling Pathway
por: Zhou, Hui, et al.
Publicado: (2023)

KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes
por: McKenzie, Andrew J., et al.
Publicado: (2016)

MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
por: Alcon, Clara, et al.
Publicado: (2022)

MEK/ERK addiction in CNL/aCML
por: Kesarwani, Meenu, et al.
Publicado: (2017)

PDRG1 promotes the proliferation and migration of GBM cells by the MEK/ERK/CD44 pathway
por: Sun, Jinmin, et al.
Publicado: (2021)

COPS3 Promotes Proliferation, Invasion, and EMT of Colorectal Cancer Cells by MEK/ERK Pathway
por: Xie, Yanchao, et al.
Publicado: (2022)

Genomic studies controvert the existence of the CUX1 p75 isoform
por: Krishnan, Manisha, et al.
Publicado: (2022)

MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma
por: de la Puente, P, et al.
Publicado: (2016)

MEK inhibition suppresses metastatic progression of KRAS‐mutated gastric cancer
por: Yamasaki, Juntaro, et al.
Publicado: (2022)

The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth
por: Hanson, Kimberley, et al.
Publicado: (2017)

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma
por: Funck-Brentano, Elisa, et al.
Publicado: (2020)

The splicing activator DAZAP1 integrates splicing control into MEK/Erk regulated cell proliferation and migration
por: Choudhury, Rajarshi, et al.
Publicado: (2014)

Fragile X mental retardation protein promotes astrocytoma proliferation via the MEK/ERK signaling pathway
por: Xing, Zhou, et al.
Publicado: (2016)

LncRNA HOTTIP promotes the proliferation and invasion of ovarian cancer cells by activating the MEK/ERK pathway
por: Liu, Jian, et al.
Publicado: (2020)

Midazolam impedes lung carcinoma cell proliferation and migration via EGFR/MEK/ERK signaling pathway
por: Zhang, Xiangchao, et al.
Publicado: (2023)

Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation
por: Lochhead, Pamela A., et al.
Publicado: (2016)

Growth Inhibitory Signaling of the Raf/MEK/ERK Pathway
por: Wu, Pui-Kei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_biihvrb4l2apot3vbfihlg1ceg